MX2010001711A - Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. - Google Patents
Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas.Info
- Publication number
- MX2010001711A MX2010001711A MX2010001711A MX2010001711A MX2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A MX 2010001711 A MX2010001711 A MX 2010001711A
- Authority
- MX
- Mexico
- Prior art keywords
- mycophenolate sodium
- extended release
- management
- dosage form
- active agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen composiciones farmacéuticas de liberación extendida que comprenden micofenolato sódico como el agente activo, en donde dicha composición exhibe un perfil de liberación característico cuando se somete a un estudio de disolución in vitro, y en donde dicho micofenolato sódico es liberado en una manera sostenida in vivo por una duración prolongada en cantidades tales que sustancialmente alivian o por lo menos reducen las posibilidades de que cause algún efecto secundario gastrointestinal asociado sin que comprometan la biodisponibilidad de dicho agente activo; la presente invención provee también un procedimiento para preparar dichas composiciones de forma de dosificación, y métodos profilácticos y/o terapéuticos de uso de dicha forma de dosificación; las composiciones de la presente invención son seguras, efectivas y bien toleradas, y son útiles para el manejo tal como profilaxis, mejora y/o tratamiento de enfermedades/trastornos indicadas como inmunosupresor, especialmente para el tratamiento o prevención del rechazo de aloinjertos o xenoinjertos de órganos, tejidos o células, por ejemplo, después de trasplante, o el manejo de enfermedades mediadas por el sistema inmune (enfermedades autoinmunes).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1714DE2007 IN2007DE01714A (es) | 2004-09-08 | 2007-08-13 | |
| PCT/IN2008/000505 WO2009022355A1 (en) | 2007-08-13 | 2008-08-11 | Extended release compositions comprising mycophenolate sodium and processes thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010001711A true MX2010001711A (es) | 2010-03-11 |
Family
ID=40350431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010001711A MX2010001711A (es) | 2007-08-13 | 2008-08-11 | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9642808B2 (es) |
| EP (1) | EP2187872A4 (es) |
| KR (1) | KR20100063059A (es) |
| AR (1) | AR070017A1 (es) |
| AU (1) | AU2008288106B2 (es) |
| BR (1) | BRPI0816231A2 (es) |
| CL (1) | CL2008002380A1 (es) |
| MX (1) | MX2010001711A (es) |
| RU (1) | RU2010109408A (es) |
| WO (1) | WO2009022355A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1985994B (zh) * | 2005-12-19 | 2011-01-12 | 康泰乐(北京)医药科技发展有限公司 | 改进的包含霉酚酸盐的包有肠溶衣的药物组合物 |
| UA96457C2 (ru) | 2006-08-03 | 2011-11-10 | Нитек Фарма Аг | Лечение ревматоидного артрита глюкокортикоидами с отсроченным высвобождением |
| EP2488173A1 (en) * | 2009-10-13 | 2012-08-22 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
| JP2013528214A (ja) | 2010-06-07 | 2013-07-08 | テリック，インコーポレイテッド | 結晶性エザチオスタット塩酸塩非溶媒和物ｄ型の調製 |
| US8759303B2 (en) | 2010-06-07 | 2014-06-24 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| JP2013528213A (ja) | 2010-06-07 | 2013-07-08 | テリック，インコーポレイテッド | エザチオスタットの錠剤製剤 |
| GB201100786D0 (en) | 2011-01-18 | 2011-03-02 | Ems Sa | Pharmaceutical compositions of immunosuppressants |
| WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
| CN110662533A (zh) * | 2017-03-13 | 2020-01-07 | 奥卡瓦制药公司 | 向非人哺乳动物递送霉酚酸活性剂的方法和组合物 |
| US10835489B2 (en) | 2018-03-09 | 2020-11-17 | University Of Saskatchewan | Modified release formulations of mycophenolate mofetil |
| CN112730680B (zh) * | 2020-12-24 | 2024-02-13 | 浙江长典药物技术开发有限公司 | 吗替麦考酚酯的溶出曲线测定方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334593A (en) * | 1990-01-13 | 1994-08-02 | Yamasa Shoyu Kabushiki Kaisha | Anxiolytic drugs |
| ID18663A (id) * | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
| GB0124953D0 (en) * | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
| AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
| GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| CN1994295A (zh) * | 2006-01-06 | 2007-07-11 | 华北制药集团新药研究开发有限责任公司 | 霉酚酸盐的包有肠溶衣的药物组合物 |
-
2008
- 2008-08-11 EP EP08789927.4A patent/EP2187872A4/en not_active Withdrawn
- 2008-08-11 WO PCT/IN2008/000505 patent/WO2009022355A1/en active Application Filing
- 2008-08-11 RU RU2010109408/15A patent/RU2010109408A/ru unknown
- 2008-08-11 KR KR1020107005378A patent/KR20100063059A/ko not_active Application Discontinuation
- 2008-08-11 MX MX2010001711A patent/MX2010001711A/es not_active Application Discontinuation
- 2008-08-11 BR BRPI0816231-0A patent/BRPI0816231A2/pt not_active IP Right Cessation
- 2008-08-11 US US12/672,180 patent/US9642808B2/en active Active
- 2008-08-11 AU AU2008288106A patent/AU2008288106B2/en not_active Ceased
- 2008-08-13 CL CL2008002380A patent/CL2008002380A1/es unknown
- 2008-08-13 AR ARP080103537A patent/AR070017A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0816231A2 (pt) | 2015-06-16 |
| US9642808B2 (en) | 2017-05-09 |
| KR20100063059A (ko) | 2010-06-10 |
| US20110223249A1 (en) | 2011-09-15 |
| RU2010109408A (ru) | 2011-09-20 |
| EP2187872A1 (en) | 2010-05-26 |
| AU2008288106A1 (en) | 2009-02-19 |
| AU2008288106B2 (en) | 2012-03-15 |
| EP2187872A4 (en) | 2013-09-18 |
| AR070017A1 (es) | 2010-03-10 |
| WO2009022355A1 (en) | 2009-02-19 |
| CL2008002380A1 (es) | 2009-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010001711A (es) | Composiciones de liberacion extendida que comprenden micofenolato sodico y procedimientos de las mismas. | |
| WO2011116139A3 (en) | Improved pharmaceutical compositions comprising cck- 8 and methods of delivery | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
| CA3094580A1 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| WO2012005500A3 (ko) | 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물 | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| WO2006113864A3 (en) | Oxindole compounds and their uses as therapeutic agents | |
| PT2210588E (pt) | Composição expansível, essencialmente isenta de ingredientes farmaceuticamente activos para o tratamento da pele humana | |
| MD20070267A (en) | Gastroresistant pharmaceutical formulation containing rifaximin | |
| IL151503A0 (en) | Therapeutic combinations of antihypertensive and antiagiogenic agents | |
| DE602006006308D1 (de) | Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten | |
| WO2010078285A3 (en) | Pharmaceutical compositions and methods of treating neurological insults | |
| HK1126119A1 (en) | Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3- propanaediol derivative as active ingredient, and its use in manufacture of medicines for preventing or treating inflammatory bowel disease 2--13- | |
| AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
| AR045957A1 (es) | Composicion farmaceutica y combinacion | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| WO2006115770A3 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| ES2781110T3 (es) | Preparación de material compuesto que comprende una capa de recubrimiento de película, que contiene un inhibidor de la 5-alfa-reductasa, y método para la producción de la preparación de material compuesto | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| WO2006125178A3 (en) | Tricyclic pyridazine compounds and their uses as therapeutic agents | |
| MX2007010886A (es) | Metodos y formulaciones de acarbosa para tratar constipacion cronica. | |
| WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |